Get the Stockscreener App
5.77
2.49%
0.14
Pre-market:
5.51
-0.26
-4.51%
Iteos Therapeutics Inc stock is traded at $5.77, with a volume of 445.39K.
It is up +2.49% in the last 24 hours and down -20.52% over the past month.
See More
Previous Close:
$5.63
Open:
$5.63
24h Volume:
445.39K
Relative Volume:
1.44
Market Cap:
$215.03M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-1.8317
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
-11.23%
1M Performance:
-20.52%
6M Performance:
-41.24%
1Y Performance:
-54.50%
1-Day Range:
$5.57
$5.835
1-Week Range:
$5.57
$6.76
52-Week Range:
$5.57
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
5.77 | 215.03M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Virtu Financial LLC - Defense World
Charles Schwab Investment Management Inc. Sells 22,939 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Charles Schwab Investment Management Inc. Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - The AM Reporter
Bank of New York Mellon Corp Sells 35,918 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc Stock: Cancer Drug Pipeline Shows Promise - Sharewise
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewswire
Game-Changing Cancer Drug Data: iTeos Reveals Best-in-Class Antibody Results at AACR - Stock Titan
Long Term Trading Analysis for (ITOS) - news.stocktradersdaily.com
Victory Capital Management Inc. Has $782,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
US Bancorp DE Acquires 4,843 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - Yahoo Finance
(ITOS) Investment Report - news.stocktradersdaily.com
Research Analysts Offer Predictions for ITOS Q1 Earnings - Defense World
Analysts Set Expectations for ITOS FY2029 Earnings - Defense World
Wells Fargo & Company Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
JPMorgan Chase & Co. Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape - TipRanks
iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush - Defense World
iTeos fait le point sur ses activités et publie ses résultats financiers pour le quatrième trimestre et l’exercice 2024 - GlobeNewswire Inc.
H.C. Wainwright maintains Buy on ITOS with $21 price target By Investing.com - Investing.com Canada
iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations - Simply Wall St
iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position - TipRanks
Y Intercept Hong Kong Ltd Purchases Shares of 18,468 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Iteos Therapeutics Inc expected to post a loss of $1.06 a shareEarnings Preview - TradingView
iTeos Therapeutics, Inc. SEC 10-K Report - TradingView
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Can iTeos' $655M War Chest Deliver on Its Promising Cancer Immunotherapy Pipeline? - StockTitan
iTeos Therapeutics (ITOS) to Release Earnings on Wednesday - Defense World
ITOS stock touches 52-week low at $7.09 amid market challenges - MSN
(ITOS) Technical Pivots with Risk Controls - Stock Traders Daily
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha
Iteos Therapeutics stock hits 52-week low at $7.05 By Investing.com - Investing.com Canada
Iteos Therapeutics stock hits 52-week low at $7.05 - Investing.com India
Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2% - MarketBeat
Empowered Funds LLC Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.2% - Defense World
(ITOS) Investment Analysis and Advice - Stock Traders Daily
Peapod Lane Capital LLC Invests $836,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC - Defense World
When (ITOS) Moves Investors should Listen - Stock Traders Daily
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully - Yahoo Finance
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Decline in Short Interest - MarketBeat
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):